This review aims to determine benefits and harms of daratumumab in addition to antineoplastic therapy compared to antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
This is a protocol.
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant
You may also be interested in:
- High-dose chemotherapy plus single vs tandem autologous transplantation as initial treatment for multiple myeloma
- Early treatment for early stage multiple myeloma may slow the disease progression but does not appear to improve survival
- Bisphosphonates in multiple myeloma
- The role of bortezomib treatment for patients with multiple myeloma
- Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
Health topics: